ENDRA Life Sciences Inc. (NDRA)
| Market Cap | 9.07M +174.6% |
| Revenue (ttm) | n/a |
| Net Income | -5.92M |
| EPS | -5.38 |
| Shares Out | 1.50M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,482 |
| Open | 5.70 |
| Previous Close | 5.68 |
| Day's Range | 5.70 - 6.37 |
| 52-Week Range | 2.96 - 9.85 |
| Beta | -0.04 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 17, 2026 |
About NDRA
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion analysis. ENDRA Life Sciences Inc. ... [Read more]
Financial Performance
Financial StatementsNews
Endra Life Sciences reported Q2 net income $160,000 vs $1.2M last year
As of June 30, 2026, ENDRA had approximately $1.7M in cash, $3.8M in restricted cash, and $1.9M in its Digital Asset Treasury. Cash used in operations during the second quarter…
ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring...
ENDRA Life Sciences Quarterly report: Q2 2026
ENDRA Life Sciences has published its Q2 2026 quarterly earnings report on August 14, 2026.
ENDRA Life Sciences Earnings release: Q2 2026
ENDRA Life Sciences released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
ASP Isotopes Issues Letter to Shareholders
DALLAS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ: ASPI) (“ASP Isotopes”, “ASPI” or the “Company”), an advanced materials company focused on developing technologies and processes for...
Join the Live Investor Webinar for Noble Africa, the Proposed ASP Isotopes Spin-Out Creating a Public Helium Company
DALLAS & ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes" or “ASPI”), an advanced materials company focused on developing technologies and processes...
Halper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing
DALLAS & ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes," “ASPI” or the "Company"), an advanced materials company focused on developing technologie...
ENDRA Life Sciences Inc trading resumes
09:35 EDT ENDRA Life Sciences (NDRA) Inc trading resumes
ENDRA Life Sciences Inc trading halted, volatility trading pause
09:30 EDT ENDRA Life Sciences (NDRA) Inc trading halted, volatility trading pause
ASP Isotopes announces proposed merger of Noble Africa, ENDRA Life Sciences
ASP Isotopes (ASPI) and ENDRA Life Sciences (NDRA) announced that ASP Isotopes’ wholly-owned subsidiary, Noble Africa (NOBA) LLC, an intermediate holding company for Renergen Limited (“Renergen”), wil...
Endra Life Sciences reports Q1 EPS ($1.09) vs. ($1.86) last year
“During the first quarter, we continued to strengthen the clinical foundation for TAEUS Liver while maintaining disciplined operational execution,” said Alexander Tokman, CEO of ENDRA Life Sciences (N...
ENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring...
ENDRA Life Sciences Quarterly report: Q1 2026
ENDRA Life Sciences has published its Q1 2026 quarterly earnings report on May 15, 2026.
Endra Life Sciences reports multi-site validation of TAEUS Liver device
Endra Life Sciences (NDRA) announced multi-site clinical validation results for TAEUS Liver that demonstrate “strong” concordance with MRI-PDFF, high reproducibility and consistent performance across ...
ENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and Reproducibility
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for the early detection and monito...
ENDRA Life Sciences Inc trading halted, volatility trading pause
15:38 EDT ENDRA Life Sciences (NDRA) Inc trading halted, volatility trading pause
ENDRA Life Sciences Inc trading resumes
15:43 EDT ENDRA Life Sciences (NDRA) Inc trading resumes
Endra Life Sciences reports Q4 EPS ($8.93) vs ($56.94) last year
“Over the past year we significantly strengthened the clinical foundation for TAEUS, demonstrating performance that we believe positions our technology alongside the current standard of care, while ma...
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring...
ENDRA Life Sciences Annual report: Q4 2025
ENDRA Life Sciences has published its Q4 2025 annual report on March 31, 2026.
ENDRA Life Sciences Earnings release: Q4 2025
ENDRA Life Sciences released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
Endra Life Sciences initiates review of strategic alternatives
ENDRA Life Sciences (NDRA)’ Board of Directors has initiated a process to evaluate a range of strategic alternatives aimed at maximizing shareholder value. As a part of this process, the…
ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring...
Endra Life Sciences announces favorable TAEUS liver device study results
Endra Life Sciences (NDRA) announced favorable results from a clinical study evaluating the measurement consistency of its TAEUS Liver device. “While MRI-PDFF remains the gold standard for liver fat q...